Tango Therapeutics
TNGX
141 hedge funds and large institutions have $1.18B invested in Tango Therapeutics in 2025 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 10 closing their positions.
797% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $173K
270% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 10
80% more capital invested
Capital invested by funds: $652M → $1.18B (+$524M)
37% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 35
23% more funds holding
Funds holding: 115 → 141 (+26)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
13.71% less ownership
Funds ownership: 117.7% → 103.99% (-14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$20.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.8M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$17M |
| 4 |
Janus Henderson Group
London,
|
+$15.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$23M |
| 2 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$20.3M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$14.9M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$11M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
-$4.7M |
TNGX Hedge Fund Activity: Q3 2025 in Review
141 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q3 2025, worth a combined $1.18B — up 80% from $652M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new TNGX positions and 10 closed out — a net gain of 27 holders — while 48 added to existing stakes and 35 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $20.9M. The largest seller was Adage Capital Partners, cutting an estimated $23M.
- 141 institutional investors held Tango Therapeutics (TNGX) as of Q3 2025, up from 115 in Q2 2025.
- Funds reported $1.18B of Tango Therapeutics stock for Q3 2025, up 80% quarter-over-quarter.
- 37 funds opened new Tango Therapeutics positions in Q3 2025 and 10 closed out, a net change of +27 holders.
- The largest Tango Therapeutics buyer in Q3 2025 was Paradigm Biocapital Advisors, an estimated $20.9M added.
- The largest Tango Therapeutics seller in Q3 2025 was Adage Capital Partners, an estimated $23M sold.
Based on aggregated 13F filings for Q3 2025.